Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Baminercept alfa 1 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | subcutaneous administration of placebo given for 12 weeks |
| One Dose | EXPERIMENTAL | BG9924 - dosage level administered as per Biogen Idec protocol |
| Second Dose | EXPERIMENTAL | BG9924 - dosage level administered as per Biogen Idec protocol |
| Third Dose | EXPERIMENTAL | BG9924 - dosage level administered as per Biogen Idec protocol |
| Fourth Dose | EXPERIMENTAL | BG9924 - dosage level administered as per Biogen Idec protocol |
| Fifth Dose | EXPERIMENTAL | BG9924 - dosage level administered as per Biogen Idec protocol |
| Name | Type | Description |
|---|---|---|
| Baminercept alfa 1 | BIOLOGICAL | experimental - one dose level |
| Placebo | BIOLOGICAL | Placebo comparator |
| Baminercept alfa 2 | BIOLOGICAL | experimental - second dose level |
| Baminercept alfa 3 | BIOLOGICAL | experimental - third dose level |
| Baminercept alfa 4 | BIOLOGICAL | experimental - fourth dose level |
| Baminercept alfa 5 | BIOLOGICAL | experimental - fifth dose level |
Key Inclusion Criteria: * Diagnosis of RA (functional class I - III) * Stable dose of MTX * Inadequate response to at least one conventional DMARD therapy Key Exclusion Criteria: * Serious local infection or systemic infection * History (Hx) of recurrent infections requiring oral or parenteral an...
Top 20 of 28 competitors
Baminercept alfa 1 is an investigational monoclonal antibody being developed for the treatment of rheumatoid arthritis. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities. The drug is being studied in patients with rheumatoid arthritis to assess its safety and efficacy.
Baminercept alfa 1 is being developed by Biogen Inc., a biotechnology company traded on the NASDAQ under the ticker symbol BIIB. The company is conducting clinical trials to evaluate the drug's potential in treating rheumatoid arthritis.
Baminercept alfa 1 is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA or other regulatory agencies. The drug is being studied in a completed Phase 2 trial for rheumatoid arthritis.
Baminercept alfa 1 has one completed Phase 2 clinical trial registered as NCT00664716, titled 'Assessment Of The Safety And Efficacy Of BG9924 In Rheumatoid Arthritis (RA) Participants'. This randomized, double-blind, placebo-controlled trial enrolled 391 participants across multiple countries including Argentina, Brazil, Hungary, Mexico, Poland, Romania, Russia, and the United Kingdom.
Yes, Baminercept alfa 1 is also known as BG9924. The clinical trial NCT00664716, which evaluated the drug in rheumatoid arthritis, used the name BG9924 in its title. Both names refer to the same investigational monoclonal antibody being developed by Biogen Inc.